Nature Medicine

AI decision support is scaling-up fast — can the evidence keep up? https://www.nature.com/articles/d41591-026-00040-4 Nature Medicine, Published online: 13 August 2026; doi:10.1038/d41591-026-00040-4 (https://www.nature.com/articles/d41591-026-00040-4)A new generation of clinical decision support tools is moving into practice, reshaping how evidence is generated, evaluated and used.

How to build an AI-driven digital organism https://www.nature.com/articles/s41591-026-04595-0 Nature Medicine, Published online: 13 August 2026; doi:10.1038/s41591-026-04595-0 (https://www.nature.com/articles/s41591-026-04595-0)Manipulating biology in the physical world is complex; the authors envision an AI-driven digital organism—a system of integrated multiscale foundation models—detailing how to construct and use such a model to advance biological and medical research.

Regulatory fragmentation as the hidden barrier to regional vaccine sovereignty https://www.nature.com/articles/s41591-026-04580-7 Nature Medicine, Published online: 13 August 2026; doi:10.1038/s41591-026-04580-7 (https://www.nature.com/articles/s41591-026-04580-7)Regulatory fragmentation as the hidden barrier to regional vaccine sovereignty

First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial https://www.nature.com/articles/s41591-026-04564-7 Nature Medicine, Published online: 12 August 2026; doi:10.1038/s41591-026-04564-7 (https://www.nature.com/articles/s41591-026-04564-7)In a multicenter, phase 2 trial, patients with treatment-naive locally advanced unresectable or metastatic triple-negative breast cancer were treated with the PD-1/vascular endothelial growth factor bispecific antibody ivonescimab plus chemotherapy, resulting in encouraging preliminary objective response rates, which support further testing in a large, randomized, phase 3 trial.

Sleep as therapy https://www.nature.com/articles/s41591-026-04582-5 Nature Medicine, Published online: 12 August 2026; doi:10.1038/s41591-026-04582-5 (https://www.nature.com/articles/s41591-026-04582-5)Once seen as a symptom, disrupted sleep is emerging as a modifiable driver of chronic illness. Drugmakers are targeting sleep pathways to reshape chronic disease biology, from pain to depression.

Frugal AI is the missing piece in cervical cancer screening https://www.nature.com/articles/s41591-026-04568-3 Nature Medicine, Published online: 12 August 2026; doi:10.1038/s41591-026-04568-3 (https://www.nature.com/articles/s41591-026-04568-3)Automated visual evaluation (AVE) could be transformative for cervical cancer screening in low-resource settings. However, AVE research has yet to yield robust clinical tools. Frugal approaches are needed that emphasize efficient, multimodal models, explainable outputs, local calibration and evaluation in real-world screening workflows.

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer https://www.nature.com/articles/s41591-026-04537-w Nature Medicine, Published online: 11 August 2026; doi:10.1038/s41591-026-04537-w (https://www.nature.com/articles/s41591-026-04537-w)Circulating tumor DNA analyses in 44 patients with pancreatic cancer receiving the RAS(ON) multi-selective inhibitor daraxonrasib as part of a phase 1/2 trial, and preclinical translational modeling approaches, identify mechanisms of acquired resistance to monotherapy and inform potential combination strategies to overcome resistance.

Reinventing health communication for the digital era https://www.nature.com/articles/s41591-026-04556-7 Nature Medicine, Published online: 11 August 2026; doi:10.1038/s41591-026-04556-7 (https://www.nature.com/articles/s41591-026-04556-7)The commissioners behind the Nature Medicine Quality Health Information for All Commission explain why improving access to accurate, timely and evidence-based information is now essential to global health.

Anti-aging interventions need less hype and more clinical evidence https://www.nature.com/articles/s41591-026-04611-3 Nature Medicine, Published online: 11 August 2026; doi:10.1038/s41591-026-04611-3 (https://www.nature.com/articles/s41591-026-04611-3)The aging field needs to develop reliable biomarkers of aging and a solid evidence base for the safety and efficacy of anti-aging treatments.

From RAS inhibitor resistance to rational combination strategies https://www.nature.com/articles/s41591-026-04529-w Nature Medicine, Published online: 11 August 2026; doi:10.1038/s41591-026-04529-w (https://www.nature.com/articles/s41591-026-04529-w)As new drugs that target mutant RAS redefine the therapeutic landscape in the treatment of pancreatic cancer, understanding and intercepting resistance is critical; a new study reveals mechanisms of acquired genetic resistance to daraxonrasib, highlighting putative combination approaches.

Global access to different classes of diabetes medicines: a framework for targeted policy actions https://www.nature.com/articles/s41591-026-04579-0 Nature Medicine, Published online: 10 August 2026; doi:10.1038/s41591-026-04579-0 (https://www.nature.com/articles/s41591-026-04579-0)Global access to different classes of diabetes medicines: a framework for targeted policy actions

Editorial Expression of Concern: CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis https://www.nature.com/articles/s41591-026-04620-2 Nature Medicine, Published online: 10 August 2026; doi:10.1038/s41591-026-04620-2 (https://www.nature.com/articles/s41591-026-04620-2)Editorial Expression of Concern: CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis

A clinically validated framework for auditing AI chatbot behavior in mental health interactions https://www.nature.com/articles/s41591-026-04577-2 Nature Medicine, Published online: 07 August 2026; doi:10.1038/s41591-026-04577-2 (https://www.nature.com/articles/s41591-026-04577-2)Across 810 conversations, an evaluation framework finds that AI chatbots often amplify simulated users’ psychological vulnerabilities, revealing persistent safety risks in mental health contexts.

Large-scale whole-genome sequencing reveals the landscape and health implications of de novo mutations https://www.nature.com/articles/s41591-026-04585-2 Nature Medicine, Published online: 07 August 2026; doi:10.1038/s41591-026-04585-2 (https://www.nature.com/articles/s41591-026-04585-2)This whole-genome sequencing study based on 7,851 parent−offspring families shows that parental age and assisted reproductive technologies influence the number and types of de novo mutations, highlighting potential health impacts and the need to optimize reproductive practices.

Psilocybin-assisted therapy for treatment-resistant major depressive disorder in a public healthcare setting: a randomized controlled trial https://www.nature.com/articles/s41591-026-04541-0 Nature Medicine, Published online: 06 August 2026; doi:10.1038/s41591-026-04541-0 (https://www.nature.com/articles/s41591-026-04541-0)In a publicly funded trial undertaken in the NHS in England, 60 adults with treatment-resistant major depression received psilocybin or placebo alongside standardized psychological support, with psilocybin showing significant improvements in depression symptoms, good tolerability and support for further research in public healthcare settings.

Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial https://www.nature.com/articles/s41591-026-04557-6 Nature Medicine, Published online: 06 August 2026; doi:10.1038/s41591-026-04557-6 (https://www.nature.com/articles/s41591-026-04557-6)In this phase 1 dose-escalation trial, intracranial delivery of B7-H3-targeting chimeric antigen receptor T cell therapy in patients with glioblastoma showed no dose-limiting toxicity signals and encouraging signals of clinical benefit.

Dronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trial https://www.nature.com/articles/s41591-026-04546-9 Nature Medicine, Published online: 05 August 2026; doi:10.1038/s41591-026-04546-9 (https://www.nature.com/articles/s41591-026-04546-9)A randomized controlled trial found that dronabinol significantly reduced both the frequency and intensity of nightmares in patients with PTSD over 10 weeks, compared with placebo.